Bicycle Therapeutics Plc (BCYC)
3.86
+0.03
(+0.78%)
USD |
NASDAQ |
Sep 11, 16:00
3.88
+0.02
(+0.52%)
After-Hours: 20:00
Bicycle Therapeutics Enterprise Value : -300.39M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | -300.39M |
| September 10, 2026 | -301.90M |
| September 09, 2026 | -293.08M |
| September 08, 2026 | -284.27M |
| September 04, 2026 | -278.22M |
| September 03, 2026 | -281.24M |
| September 02, 2026 | -278.22M |
| September 01, 2026 | -288.30M |
| August 31, 2026 | -286.79M |
| August 28, 2026 | -283.26M |
| August 27, 2026 | -276.71M |
| August 26, 2026 | -275.45M |
| August 25, 2026 | -273.69M |
| August 24, 2026 | -276.71M |
| August 21, 2026 | -274.70M |
| August 20, 2026 | -281.24M |
| August 19, 2026 | -286.28M |
| August 18, 2026 | -293.84M |
| August 17, 2026 | -293.34M |
| August 14, 2026 | -298.37M |
| August 13, 2026 | -294.34M |
| August 12, 2026 | -290.31M |
| August 11, 2026 | -287.29M |
| August 10, 2026 | -287.79M |
| August 07, 2026 | -284.77M |
| Date | Value |
|---|---|
| August 06, 2026 | -294.85M |
| August 05, 2026 | -294.85M |
| August 04, 2026 | -296.36M |
| August 03, 2026 | -299.88M |
| July 31, 2026 | -300.39M |
| July 30, 2026 | -292.83M |
| July 29, 2026 | -300.39M |
| July 28, 2026 | -296.36M |
| July 27, 2026 | -295.85M |
| July 24, 2026 | -299.88M |
| July 23, 2026 | -285.28M |
| July 22, 2026 | -282.76M |
| July 21, 2026 | -285.28M |
| July 20, 2026 | -285.28M |
| July 17, 2026 | -282.76M |
| July 16, 2026 | -284.27M |
| July 15, 2026 | -282.25M |
| July 14, 2026 | -282.76M |
| July 13, 2026 | -275.70M |
| July 10, 2026 | -272.68M |
| July 09, 2026 | -284.27M |
| July 08, 2026 | -279.23M |
| July 07, 2026 | -274.19M |
| July 06, 2026 | -275.70M |
| July 02, 2026 | -275.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Autolus Therapeutics Plc | 665.07M |
| Akari Therapeutics Plc | 12.72M |
| Biodexa Pharmaceuticals Plc | -- |
| Cellectis SA | 249.60M |
| DBV Technologies SA | 488.42M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -50.42M |
| Revenue (Quarterly) | 0.6301M |
| Total Expenses (Quarterly) | 51.05M |
| EPS Diluted (Quarterly) | -0.7224 |
| Gross Profit Margin (Quarterly) | -69.64% |
| Profit Margin (Quarterly) | -8.00K% |
| Earnings Yield | -70.76% |
| Normalized Earnings Yield | -70.76 |